Log in

NASDAQ:MEIP - MEI Pharma Stock Price, Forecast & News

$2.52
+0.17 (+7.23 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$2.33
Now: $2.52
$2.54
50-Day Range
$1.68
MA: $2.09
$2.52
52-Week Range
$1.44
Now: $2.52
$3.41
Volume719,890 shs
Average Volume523,236 shs
Market Capitalization$256.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73
MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEIP
Previous SymbolNASDAQ:MSHL
CUSIPN/A
Phone858-369-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.91 million
Book Value$0.67 per share

Profitability

Net Income$-16,820,000.00
Net Margins-514.11%

Miscellaneous

Employees32
Market Cap$256.48 million
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable

Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.


MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How were MEI Pharma's earnings last quarter?

MEI Pharma Inc (NASDAQ:MEIP) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The business earned $1.16 million during the quarter, compared to the consensus estimate of $1.11 million. MEI Pharma had a negative net margin of 514.11% and a negative return on equity of 79.27%. View MEI Pharma's Earnings History.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for MEI Pharma.

What price target have analysts set for MEIP?

3 analysts have issued 12-month price objectives for MEI Pharma's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate MEI Pharma's stock price to reach $10.00 in the next year. This suggests a possible upside of 296.8% from the stock's current price. View Analyst Price Targets for MEI Pharma.

What is the consensus analysts' recommendation for MEI Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.

Has MEI Pharma been receiving favorable news coverage?

Headlines about MEIP stock have trended negative on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MEI Pharma earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for MEI Pharma.

Are investors shorting MEI Pharma?

MEI Pharma saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 367,900 shares, an increase of 25.2% from the December 15th total of 293,800 shares. Based on an average daily volume of 418,900 shares, the short-interest ratio is presently 0.9 days. Currently, 0.6% of the shares of the stock are short sold. View MEI Pharma's Current Options Chain.

Who are some of MEI Pharma's key competitors?

What other stocks do shareholders of MEI Pharma own?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:
  • Dr. Daniel P. Gold, CEO, Pres & Director (Age 65)
  • Mr. Brian G. Drazba CPA, Sec. & CFO (Age 58)
  • Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 55)
  • Dr. Robert D. Mass M.D., Chief Medical Officer (Age 65)
  • Mr. David A. Walsey, VP of IR & Corp. Communications

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $2.52.

How big of a company is MEI Pharma?

MEI Pharma has a market capitalization of $256.48 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.

What is MEI Pharma's official website?

The official website for MEI Pharma is http://www.meipharma.com/.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]


MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  315 (Vote Outperform)
Underperform Votes:  255 (Vote Underperform)
Total Votes:  570
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel